Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$36.01 - $74.24 $6.39 Million - $13.2 Million
-177,500 Reduced 38.79%
280,100 $11.8 Million
Q1 2022

May 16, 2022

BUY
$60.27 - $81.57 $24,108 - $32,627
400 Added 0.09%
457,600 $30.8 Million
Q4 2021

Feb 14, 2022

SELL
$65.85 - $96.21 $7.92 Million - $11.6 Million
-120,300 Reduced 20.83%
457,200 $37.6 Million
Q3 2021

Nov 15, 2021

SELL
$73.2 - $107.87 $3.56 Million - $5.24 Million
-48,600 Reduced 7.76%
577,500 $47.5 Million
Q2 2021

Aug 16, 2021

BUY
$60.45 - $84.26 $259,935 - $362,318
4,300 Added 0.69%
626,100 $48.2 Million
Q1 2021

May 17, 2021

SELL
$58.19 - $91.37 $7.23 Million - $11.3 Million
-124,200 Reduced 16.65%
621,800 $41.1 Million
Q4 2020

Feb 16, 2021

BUY
$20.19 - $84.93 $5.34 Million - $22.5 Million
264,532 Added 54.94%
746,000 $63.4 Million
Q2 2020

Aug 14, 2020

BUY
$29.88 - $56.74 $5.87 Million - $11.1 Million
196,468 Added 68.94%
481,468 $16.1 Million
Q1 2020

May 15, 2020

BUY
$33.0 - $54.5 $1.16 Million - $1.91 Million
35,000 Added 14.0%
285,000 $11.5 Million
Q4 2019

Feb 14, 2020

BUY
$15.39 - $44.38 $1.54 Million - $4.44 Million
100,000 Added 66.67%
250,000 $10.3 Million
Q3 2018

Nov 14, 2018

BUY
$16.05 - $16.87 $2.41 Million - $2.53 Million
150,000 New
150,000 $2.53 Million

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.02B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Rock Springs Capital Management LP Portfolio

Follow Rock Springs Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Rock Springs Capital Management LP with notifications on news.